Christiansen v. Pharmaceuticals
Steven B. Christiansen, on behalf of himself and a class of similarly situated investors v. Spectrum Pharmaceuticals, Inc., Thomas J. Riga, Francois J. Lebel, and Nora E. Brennan; Nizar Sami Ayoub, on behalf of himself and a class of similarly situated investors v. Spectrum Pharmaceuticals, Inc., Thomas J. Riga, Francois J. Lebel, and Nora E. Brennan
- Valerie Caproni
- 1:22-cv-10292
- U.S. District Court · Southern District of New York
- 9
Counsel of record per CourtListener. Firm names are approximate and have been consolidated across spelling variants.
In Christiansen v. Spectrum Pharmaceuticals, Judge Caproni denied Christiansen’s request that she step aside.
The ruling affects Steven B. Christiansen, Nizar Sami Ayoub, Spectrum Pharmaceuticals, Inc., Thomas J. Riga, Francois J. Lebel, and Nora E. Brennan by keeping Judge Valerie Caproni on the case and closing the motions at Docket Numbers 208 and 209.
What happened
Steven B. Christiansen and Nizar Sami Ayoub are named plaintiffs in a case against Spectrum Pharmaceuticals, Inc., and three individuals. Christiansen asked Judge Valerie Caproni to step aside, arguing that her impartiality could reasonably be questioned.
Christiansen pointed to the court’s earlier decision disqualifying him as lead plaintiff and to statements attributed to Ayoub about a proposed settlement. The opinion also states that the court found no evidence that Ayoub disclosed nonpublic information.
Judge Valerie Caproni denied the request to step aside, finding that no reasonable person would view the denial of Christiansen’s motion concerning Ayoub as evidence of bias. The clerk was directed to close the motions at Docket Numbers 208 and 209.
The detailed version
- Christiansen v. Pharmaceuticals · No. 1:22-cv-10292
- Valerie Caproni
- July 16, 2026
Background
Steven B. Christiansen filed a request under 28 U.S.C. § 455(a) asking Judge Valerie Caproni to recuse herself—that is, to step aside—from this investor case. The request argued that the judge’s impartiality might reasonably be questioned.
Christiansen relied on the court’s August 4, 2025 order disqualifying him as lead plaintiff for an asserted violation of a nondisclosure agreement. He also referred to statements attributed to co-lead plaintiff Nizar Sami Ayoub about a proposed $7 million settlement. The opinion states that the court found no evidence that Ayoub disclosed nonpublic information.
Court’s Ruling
The court denied the request for recusal. Judge Caproni stated that no reasonable individual would view the court’s denial of Christiansen’s motion to disqualify Ayoub as an indication of bias. The court also stated that it saw no reason to recuse itself. The clerk was directed to close the open motions at Docket Numbers 208 and 209.
Effect of the Order
This order resolves the recusal request and directs closure of the two identified motions. It does not decide the investors’ underlying claims against Spectrum Pharmaceuticals, Inc., Thomas J. Riga, Francois J. Lebel, or Nora E. Brennan.
Read the full 9-page opinion on CourtListener, the free public archive maintained by the Free Law Project.